# US 2015/0174138 A1 · Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0174138 A1
- Document ID: US20150174138A1
- Status: Published application
- Kind: A1
- Application number: 14/409,138
- Filed: 2013-06-19
- Published: 2015-06-25
- Earliest claimed: 2012-06-19
- Assignees: The Broad Institute, Inc.; The Brigham and Women's Hospital, Inc.; The General Hospital Corporation d/b/a Massachusetts General Hospital; Dana-Farber Cancer Institute, Inc.
- Applicants: The Broad Institute, Inc.; The Brigham and Women's Hospital, Inc.; The General Hospital Corporation d/b/a Massachusetts General Hospital; Dana-Farber Cancer Institute, Inc.
- Inventors: Bradley E. Bernstein; Jon C. Aster; James E. Bradner; Birgit Knoechel; Christopher J. Ott; David Root
- Web page: https://patentgrep.com/patent/US20150174138A1

## CPC

- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor.

## Claims

### Claim 1

A method comprising:
administering to a subject having cancer
(i) a bromodomain inhibitor and/or
(ii) a Bcl-2 inhibitor, and
a Notch pathway inhibitor, in an effective amount to treat the cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is resistant to a previously-administered Notch pathway inhibitor.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the cancer is characterized by the presence of a Notch pathway activation mutation.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the cancer is characterized by abnormal increased HPI-alpha, HPI-beta, and/or HPI-gamma level.

### Claim 5 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the cancer is characterized by a chromatin compactness or a marker thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the bromodomain inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the Bcl-2 inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the bromodomain inhibitor, the Bcl-2 inhibitor and the Notch pathway inhibitor are administered.

### Claim 9 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the bromodomain inhibitor, the Bcl-2 inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 10

A method comprising:
administering to a subject having cancer
(i) a bromodomain inhibitor and/or
(ii) a Bcl-2 inhibitor,
in an effective amount to treat the cancer, wherein the cancer is characterized by the presence of a Notch pathway activation mutation.

### Claim 11 (depends on 10)

The method of claim 10, further comprising identifying the subject having cancer characterized by the presence of a Notch pathway activation mutation.

### Claim 12 (depends on 10, 11)

The method of claim 10 or 11, further comprising administering to the subject a Notch pathway inhibitor in an effective amount to treat the cancer.

### Claim 13 (depends on 12)

The method of claim 12, wherein the bromodomain inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 14 (depends on 12)

The method of claim 12, wherein the Bcl-2 inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 15 (depends on 12)

The method of claim 12, wherein the bromodomain inhibitor, the Bcl-2 inhibitor, and the Notch pathway inhibitor are administered.

### Claim 16 (depends on 12)

The method of claim 12, wherein the bromodomain inhibitor, the Bcl-2 inhibitor, and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 17

A method comprising:
administering to a subject having cancer
(i) a bromodomain inhibitor and/or
(ii) a Bcl-2 inhibitor
in an effective amount to treat the cancer, wherein the cancer is resistant to treatment with a Notch pathway inhibitor.

### Claim 18 (depends on 17)

The method of claim 17, further comprising administering to the subject a Notch pathway inhibitor in an effective amount to treat the cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the bromodomain inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 20 (depends on 17)

The method of claim 17, wherein the Bcl-2 inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 21 (depends on 17)

The method of claim 17, wherein the bromodomain inhibitor, the Bcl-2 inhibitor, and the Notch pathway inhibitor are administered.

### Claim 22 (depends on 17)

The method of claim 17, wherein the bromodomain inhibitor, the Bcl-2 inhibitor, and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 23

A method comprising:
administering to a subject having cancer
(i) a bromodomain inhibitor and/or
(ii) a Bcl-2 inhibitor
in an effective amount to treat the cancer, wherein the cancer is characterized by abnormal increased HPI level, wherein the HPI level is HPI-alpha level, HPI-beta level and/or HPI-gamma level.

### Claim 24 (depends on 23)

The method of claim 23, further comprising identifying a subject having cancer characterized by the abnormal increased HPI level.

### Claim 25 (depends on 23, 24)

The method of claim 23 or 24, further comprising administering to the subject a Notch pathway inhibitor in an effective amount to treat the cancer.

### Claim 26 (depends on 25)

The method of claim 25, wherein the bromodomain inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 27 (depends on 25)

The method of claim 25, wherein the Bcl-2 inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 28 (depends on 25)

The method of claim 25, wherein the bromodomain inhibitor, the Bcl-2 inhibitor, and the Notch pathway inhibitor are administered.

### Claim 29 (depends on 25)

The method of claim 25, wherein the bromodomain inhibitor, the Bcl-2 inhibitor and the Notch pathway inhibitor are administered concurrently or sequentially.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the bromodomain inhibitor, the Bcl-2 inhibitor and/or the Notch pathway inhibitor is a small compound or inhibitory nucleic acid molecule.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the inhibitory nucleic acid molecule is an siRNA, shRNA, or antisense nucleic acid molecule.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the bromodomain inhibitor is a BET inhibitor.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-32, wherein the bromodomain inhibitor is JQ1 or a derivative thereof.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the Bcl-2 inhibitor is G3139, GX15-070, ABT-737 or ABT-199.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the Notch pathway inhibitor is a gamma secretase inhibitor.

### Claim 36

A method comprising:
(a) measuring nucleus size in a tumor sample from a subject; and
(b) comparing nucleus size in the tumor sample to a control,
wherein a decreased nucleus size in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.

### Claim 37 (depends on 36)

The method of claim 36, wherein the nucleus size is nucleus diameter or nucleus volume.

### Claim 38

A method comprising:
(a) measuring HPI level in a tumor sample from a subject; and
(b) comparing the HPI level in the tumor sample to a control,
wherein an increased HPI level in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor,
wherein the HPI level is HPI-alpha level, HPI-beta level, and/or HPI-gamma level.

### Claim 39

A method comprising:
(a) measuring level of a chromatin state biomarker (CSB) in a tumor sample from a subject, the CSB selected from:
(i) a first CSB group consisting of NPM1, NARG1, RCC1, SSRP1, PRMT3, SAP30, CBX6, CHMP2B, UBE2M, WDR77, HMGB1, CARM1, USP13, HDAC4, COQ3, SET, GATAD2A, PRMT6, HMG20B, DNMT1, ADA, SS18, UBE3A, ZMYND11, and NOC2LL (“Group I CSB”); and
(ii) a second CSB group consisting of UTX, SIN3A, SAP30L, FLJ20309, RCOR2, ARID5A, UBE2Q2, TRIM24, BAZ2B, SMYD3, EZH2, PHF1, PHF2, BCR, SMARCD3, BMI1, CHD6, FBXL11, SIRT7, ASF1A, RCOR3, CBX4, EPC1, BRD1, and BNF11 (“Group II CSB”); and
(b) comparing the Group I and/or Group II CSB level with a control, wherein a Group I CSB level that is reduced in the tumor sample compared to a control and/or a Group II CSB level that is elevated in the tumor sample compared to a control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.

### Claim 40

A method comprising:
(a) measuring a level of a biomarker in a tumor sample from a subject, the biomarker selected from DTX1, HES4, CD1d, ETS1, ETV6, Runx1, Bcl-2, MYC and CD52; and
(b) comparing the biomarker level with a control,
wherein a level of DTX1, HES4, or CD1d that is reduced in the tumor sample compared to the control and/or a level of ETS1, ETV6, Runx1, CD52, MYC or Bcl-2 that is elevated in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.

### Claim 41 (depends on 38, 39, 40)

The method of any one of claims 38-40, wherein the level is an mRNA level or a protein level.

### Claim 42

A method comprising:
(a) measuring a level of histone modification in a tumor sample from a subject, the histone modification selected from H3K27me3 and H3K9me3; and
(b) comparing the histone modification level with a control,
wherein a level of histone modification that is elevated in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.

### Claim 43

A method comprising:
(a) measuring a level of H3K27Ac histone modification in a tumor sample from a subject; and
(b) comparing the H3K27Ac histone modification level with a control, wherein a level of H3K27Ac histone modification that is reduced in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.

### Claim 44

A method comprising:
(a) measuring a level of H3K4me1 histone modification at a site of elevated H3K27Ac histone modification; and
(b) comparing the H3K4me1 histone modification level with a control, wherein a level of H3K4me1 histone modification at a site of elevated H3K27Ac histone modification that is elevated in the tumor sample compared to the control identifies a subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.

### Claim 45 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 36-44, wherein the control is a nucleus size, an HPI-alpha level, an HPI-beta level, an HPI-gamma level, a CSB level, a histone modification level or a biomarker level selected from DTX1, HES4, CD1d, ETS1, ETV6, Runx1, Bcl-2, MYC and CD52 in a non-tumor sample.

### Claim 46 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 36-45, wherein the control is a predetermined threshold.

### Claim 47 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 36-46, further comprising identifying the subject to be treated with a bromodomain inhibitor and/or Bcl-2 inhibitor.

### Claim 48 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 36-47, further comprising administering to the identified subject a bromodomain inhibitor and/or Bcl-2 inhibitor in an effective amount.

### Claim 49 (depends on 48)

The method of claim 48, further comprising administering to the identified subject a Notch pathway inhibitor in an effective amount.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 1-49, wherein the cancer or tumor is a T-ALL.

### Claim 51 (depends on 50)

The method of claim 50, wherein the T-ALL is resistant to a Notch pathway inhibitor.

### Claim 52

A method comprising:
administering to a subject having cancer an inhibitor of ARID3B, EZH2, PRMT2, SND1, BRD1, SUV39H1, PRMT5, SS18, BRD4, KDM5D, PRMT7, STAG3L1, CD2BP2, MLL5, SUDS3, CHD1, MINA, CHD8, MORF4L1, or CHRAC1, wherein the cancer is resistant to a Notch pathway inhibitor.

### Claim 53 (depends on 52)

The method of claim 52, further comprising administering to the subject a Notch pathway inhibitor.

### Claim 54 (depends on 52, 53)

The method of claim 52 or 53, further comprising administering to the subject a bromodomain inhibitor and/or a Bcl-2 inhibitor in an effective amount to treat the cancer.

### Claim 55 (depends on 52, 53, 54)

The method of any one of claims 52-54, wherein the inhibitor is an shRNA, an siRNA, or an antisense nucleic acid molecule.
